Core Viewpoint - 嘉涛(香港)控股 reported a total revenue of approximately HKD 174 million for the six months ending September 30, 2025, representing an increase of about 17.8% compared to the same period in 2024 [1] - The profit attributable to the company's owners was approximately HKD 27 million, reflecting a year-on-year increase of about 5.1% [1] - The board of directors did not recommend the payment of an interim dividend for the six months ending September 30, 2025, consistent with the previous period where no dividend was declared [1] Financial Performance - Total revenue for the six months ending September 30, 2025, was approximately HKD 174 million, up 17.8% from the previous year [1] - Profit attributable to owners was approximately HKD 27 million, an increase of 5.1% year-on-year [1] - No interim dividend was proposed for the current period, maintaining the same stance as the previous year [1] Business Development - In 2022, the company expanded into the medical diagnostics and health check market in Hong Kong [1] - The company offers a variety of healthcare services, including general health checks, X-rays, ECGs, mammograms, ultrasounds, DEXA bone density tests, and various laboratory tests [1] - As of March 31, 2025, the company operated three medical health check centers in three regions of Hong Kong [1] - The company terminated its medical and laboratory services in April 2025 to focus resources on developing elderly care services [1]
嘉涛(香港)控股(02189.HK)中期拥有人应占溢利约2700万港元 同比增加约5.1%